| 000 | 05379nam a22004095i 4500 | ||
|---|---|---|---|
| 001 | 76043 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230207040206.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131010s2013 xxu| s |||| 0|eng d | ||
| 020 | _a9781461484325 | ||
| 024 | 7 |
_a10.1007/978-1-4614-8432-5 _2doi |
|
| 040 | _aES-MaUEC | ||
| 050 | 4 |
_aRS192 _b.M45 2013 EB |
|
| 082 | 0 | 4 | _a610 |
| 245 | 0 | 0 |
_aMelt extrusion : _bmaterials, technology and drug product design _cedited by Michael A. Repka, Nigel Langley, James DiNunzio |
| 260 |
_aNew York _bSpringer International Publishing _c2013 |
||
| 300 |
_a1 recurso en línea (XII, 474 p.) _b266 ilustraciones, 125 ilustraciones en color |
||
| 336 |
_aTexto (visual) _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 490 | 0 |
_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v9 |
|
| 505 | 0 | _aMelt Extrusion in Drug Delivery: Three Decades of Progress -- Twin Screw Extrusion for Pharmaceutical Processes -- Properties and Applications of Polyvinyllactam Polymers -- Properties and Applications of Hypromellose Acetate Succinate (HPMCAS) for Solubility Enhancement Using Melt Extrusion -- Cellulose Ethers for Extrusion Applications -- Properties and Applications of Polyethylene Oxide and Ethylcellulose for Tamper Resistance and Controlled Drug Delivery -- Formulation Development of Amorphous Solid Dispersions Prepared by Melt Extrusion -- Non-Sink In Vitro Dissolution Testing of Amorphous Solid Dispersions -- Manufacture of Pharmaceutically Relevant Materials by Mechanochemistry Using Twin Screw Extrusion -- Melt Extruded Controlled Release Dosage Forms -- Excipient/API Melt Processing via Injection Molding -- Devices and Implants Prepared Using Hot Melt Extrusion -- Solid Lipid Extrusion -- Formulation, Bioavailability and Manufacturing Process Enhancement: Novel Applications of Melt Extrusion in Enabling Product Development -- Hot Melt Extrusion as a Continuous Pharmaceutical Manufacturing Process -- Hot-Melt Extrusion Process Design Using Process Analytical Technology -- Consistency of Pharmaceutical Products: An FDA Perspective on Hot-melt Extrusion Process -- Melt Extrusion: A Commercial Perception to Practicality -- Future Trends | |
| 520 | _aThis inclusive text describes hot melt extrusion for pharmaceutical applications, focusing on the materials used for the preparation of solid dispersions, fundamentals for preparing such systems and novel applications using extrusion technology. Highlighting viewpoints from the academic, excipient, equipment, product development and regulatory communities, this comprehensive text compiles input from industry thought leaders to illustrate strategies and technologies for applying hot melt extrusion for drug product development while also providing insight into the path forward for the technology in years to come. Dr. Michael A. Repka is Chair and Professor of the Department of Pharmaceutics at The University of Mississippi, as well as Director of the Pii Center for Pharmaceutical Technology. His research interests include the solubilization and delivery of poorly soluble bioactives via hot melt extrusion technology. Dr. Repka has established himself as an expert in this major pharmaceutical processing field through his numerous peer-reviewed publications, presentations and scientific talks. Dr. Nigel Langley is currently Head of Marketing and Technical Sales at BASF Corporation where he is responsible for the promotion and technical support for BASF's pharmaceutical excipients and APIs to the Pharmaceutical Industry in North America. He has a strong interest in solubilization including hot melt extrusion. He received his Ph.D. in Liquid Crystals from Hull University, U.K., and an M.B.A. from Leeds University, U.K. Prior to joining BASF, he worked for Croda International in the U.K., Japan and the United States. Dr. James DiNunzio is currently an Associate Principal Scientist at Merck & Co., Inc. where he serves as a member of the Hot Melt Extrusion Technology Development Team. He received his Ph.D. in Pharmacy from the University of Texas at Austin and holds M.S. and B.S. degrees in Chemical Engineering from Columbia University and SUNY Buffalo, respectively. His research interests include formulation design of amorphous dispersions, development of controlled release products using melt extrusion, continuous manufacturing and engineering of directly shaped drug products | ||
| 942 |
_2lcc _cLE |
||
| 988 | _aEBOOK, EBSPRINGERrevisado | ||
| 650 | 7 |
_aTecnología farmacéutica _0comprobar BNE20030698632 _2embne _9161127 |
|
| 650 | 7 |
_aDrogas de diseño _0comprobar BNE20004394303 _2embne _9157991 |
|
| 700 | 1 |
_aRepka, Michael A. _eeditor literario _984874 _0Local |
|
| 700 | 1 |
_aLangley, Nigel _eeditor literario _984875 _0Local |
|
| 700 | 1 |
_aDiNunzio, James _eeditor literario _984876 _0Local |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-8432-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 901 | _ai9781461484325 | ||
| 907 |
_a.b12816619 _b10-10-17 _c01-10-14 |
||
| 998 |
_am _a_alco _a_vill _b08-05-17 _cm _dz _eb _feng _gxxu _h0 |
||
| 945 |
_aRS192 .M45 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545835 _z06-04-17 |
||
| 999 |
_c76043 _d76043 _x1 |
||